KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Invested Capital (2016 - 2025)

Jazz Pharmaceuticals has reported Invested Capital over the past 16 years, most recently at $9.7 billion for Q4 2025.

  • Quarterly Invested Capital fell 5.15% to $9.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.7 billion through Dec 2025, down 5.15% year-over-year, with the annual reading at $9.7 billion for FY2025, 5.15% down from the prior year.
  • Invested Capital was $9.7 billion for Q4 2025 at Jazz Pharmaceuticals, up from $9.3 billion in the prior quarter.
  • Over five years, Invested Capital peaked at $10.9 billion in Q2 2021 and troughed at $5.9 billion in Q1 2021.
  • The 5-year median for Invested Capital is $9.4 billion (2023), against an average of $9.4 billion.
  • Biggest five-year swings in Invested Capital: skyrocketed 107.24% in 2021 and later fell 17.08% in 2022.
  • Tracing JAZZ's Invested Capital over 5 years: stood at $10.0 billion in 2021, then fell by 12.03% to $8.8 billion in 2022, then increased by 7.26% to $9.4 billion in 2023, then increased by 7.96% to $10.2 billion in 2024, then dropped by 5.15% to $9.7 billion in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $9.7 billion, $9.3 billion, and $9.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.